|
|
by John Steuart on May 14th, 2012 
On Wednesday May 16 I will be presenting at the iMedicine & Mobile Life Sciences World Summit concerning smartphones as the next frontier in medical imaging, telemedicine and EMRs. I am presenting with Tobin Arthur of Cureus. Cureus is revolutionizing medical publishing and is founded by John Adler, a famous neurosurgeon at Stanford. Physicians today use their smartphones 5 times a day on average and these smartphones are another form of clinical decision support . . .
→ Read full post: Smartphones as the Next Frontier in Medical Imaging, EMRs and Telemedicine
by Brad Webb on April 2nd, 2012 
I’m excited that we have recently added a new portfolio company Genalyte to the Claremont Creek digital healthcare family. I’ll be joining the Board, and I am looking forward to working with founder and CEO Cary Gunn and the Genalyte team. Genalyte is a developer and manufacturer of advanced biomarker detection technology strategically located right in the center of the San Diego life science community. Claremont Creek Ventures participated in a $11.8 . . .
→ Read full post: My newest investment: Genalyte — Augmenting Claremont Creek Ventures’ Digital Healthcare Tools Portfolio
by John Steuart on March 8th, 2012 
March 7, 2012 source: Angel Capital Association (ACA)
AssureRx Health, Inc. Receives 2012 ACA Luis Villalobos Award for Innovation
Angel Capital Association Recognizes Company For Industry-leading Personalized Medicine Solution
Hats off to one of my portfolio companies, AssureRx today received the the 2012 Luis Villalobos Award from the Angel Capital Association (ACA), the trade association of leading angel investment groups in North America. This award recognizes the most ingenious and innovative . . .
→ Read full post: Claremont Creek Ventures portfolio company AssureRx Health wins award for innovation
by Claremont Creek Alerts on January 18th, 2012 
January 18, 2012 source: MedCity News
Personalized medicine company AssureRx Health has released the next-generation version of its genetic screening test for psychiatric drugs.
The Cincinnati-area company’s GeneSightRx test, which helps doctors pick the right psychiatric drugs for patients based on their genes, was launched in 2009. The test uses a cheek swab, mathematical algorithms and bioinformatics to narrow drug choices to those that work with a patient’s genes.
. . .
→ Read full post: Claremont Creek Ventures’ portfolio company AssureRX updates its psychiatric drugs screening test
by Claremont Creek Alerts on December 15th, 2011 
September 9, 2011 source: originally published in the San Francisco Business Times
Photo: Spencer Brown The winner “is the company that’s going to help families,” says GSN CEO Rabinowitz.
Gene Security Network’s race to develop safer, more accurate prenatal test is all business for Matt Rabinowitz — and it’s personal.
A relative of Rabinowitz, Gene Security Network’s CEO, took a blood test for the likelihood of Down’s syndrome in her unborn baby and . . .
→ Read full post: Claremont Creek Ventures’ portfolio company Gene Security Network in race for prenatal test
by Claremont Creek Alerts on October 10th, 2011 
October 9, 2011 source: CBS News
As part of CBS morning news, TIBION was profiled by correspondent Barry Peterson. At approximately four minutes 21 seconds into the video, see how TIBION stands out. We are proud of our portfolio company that is getting worldwide recognition.
The next step in bionics
…
The new world of high-tech prosthetics includes the Tibion Bionic limb, that helps stroke victims re-learn how to use . . .
→ Read full post: Claremont Creek Ventures portfolio company Tibion’s VP of Engineering Matt Murphy shows off the Tibion Bionic Limb on CBS Morning News
by John Steuart on September 12th, 2011 
Claremont Creek Ventures portfolio company Gene Security Network (GSN) achieved a technical breakthrough that even Dear Abby can crow about. Never before, have scientists and clinicians been about to measure fetal DNA in a pregnant woman’s blood with enough accuracy to determine paternity or relevant information about the baby in utero — until now. If you are curious why this service might be helpful, see Dear Abby’s recent column below.
In . . .
→ Read full post: Why Dear Abby loves this company (and you should, too)
by Brad Webb on September 12th, 2011 
It is always great to brag and cheer about one of our portfolio companies. Working with portfolio companies to help them succeed is one of a VC’s key jobs, and helping build an executive team is an area where a VC can help a lot. We are pleased to announce that AssureRx Health has just added some super people to its team. The three executives are: Dr. C. Anthony Altar, PhD, chief science officer; . . .
→ Read full post: Claremont Creek Ventures portfolio company AssureRx Health expands senior management team
by John Steuart on July 22nd, 2011
I will be moderating a panel, Venture Capitalists’ Best Practices on Commercializing Innovation at the Molecular Diagnostics World Congress on September 29, 2011 at the South San Francisco Conference Center.
Here’s the panel topic summary, hope to see you there.
Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get brought to market? The panel will explore the challenges of commercialization in a still-difficult business environment. These . . .
→ Read full post: Molecular Diagnostics World Congress, Venture Capitalists’ Best Practices on Commercializing Innovation
by Brad Webb on July 6th, 2011 July 1, 2011 source: Genetic Engineering & Biotechnology News by Brad Webb
Rapid Transition from Laboratory Discoveries to Commercialization Is Transforming Healthcare
It’s been less than a decade since a full human genome was sequenced, but already there is talk that the promise of genomics-inspired personal medicine is not being realized. I couldn’t disagree more. As we point out in this article, cardiologists, psychiatrists, and internists can now order quick and inexpensive genetics-based screening . . .
→ Read full post: Moving Quickly from an Idea to a Product
|
